Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTSNASDAQ:DWTXNASDAQ:ERNANASDAQ:SCNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSBiophytis$13.37$8.05▼$168.80$2.89M1.057,291 shs18,500 shsDWTXDogwood Therapeutics$4.65-10.2%$4.87$1.62▼$29.28$8.89M1.881.63 million shs51,803 shsERNAEterna Therapeutics$2.29-3.4%$3.03$2.08▼$39.38$142.81M5.56191,471 shs107,803 shsSCNXScienture$1.07-4.1%$0.93$0.69▼$9.55$14.03M2.86999,674 shs98,774 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSBiophytis0.00%0.00%0.00%0.00%0.00%DWTXDogwood Therapeutics-10.23%-4.91%-4.12%-24.02%+464,999,900.00%ERNAEterna Therapeutics-3.38%-15.19%-38.37%-40.57%-92.17%SCNXScienture-4.08%+0.90%+17.66%-28.22%+106,949,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSBiophytisN/AN/AN/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics1.9996 of 5 stars3.50.00.00.02.00.01.3ERNAEterna Therapeutics0.9068 of 5 stars0.05.00.00.01.81.70.0SCNXScientureN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSBiophytis 0.00N/AN/AN/ADWTXDogwood Therapeutics 3.00Buy$10.00115.05% UpsideERNAEterna Therapeutics 0.00N/AN/AN/ASCNXScienture 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BPTS, ERNA, SCNX, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/ADWTXDogwood TherapeuticsN/AN/AN/AN/A$4.94 per shareN/AERNAEterna Therapeutics$535K266.94N/AN/A$0.41 per share5.59SCNXScienture$146.90K95.49N/AN/A$0.45 per share2.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics-$5.30M-$18.04N/AN/AN/AN/A-217.12%-172.06%8/6/2025 (Estimated)ERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%8/11/2025 (Estimated)SCNXScienture-$17.84MN/A0.00∞N/AN/A-77.60%-62.29%6/25/2025 (Estimated)Latest BPTS, ERNA, SCNX, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025SCNXScientureN/A-$0.33N/A-$0.33N/A$0.01 million5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSBiophytisN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/ASCNXScientureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSBiophytisN/A0.720.72DWTXDogwood TherapeuticsN/A1.711.71ERNAEterna TherapeuticsN/A0.480.48SCNXScienture0.031.341.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSBiophytis0.05%DWTXDogwood Therapeutics9.05%ERNAEterna Therapeutics70.55%SCNXScienture5.68%Insider OwnershipCompanyInsider OwnershipBPTSBiophytis3.70%DWTXDogwood Therapeutics3.90%ERNAEterna Therapeutics1.50%SCNXScienture49.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTSBiophytis22351,000338,000Not OptionableDWTXDogwood Therapeutics51.91 million1.17 millionN/AERNAEterna Therapeutics1062.36 million5.17 millionNo DataSCNXScientureN/A13.12 million4.40 millionN/ABPTS, ERNA, SCNX, and DWTX HeadlinesRecent News About These CompaniesScienture Holdings, Inc. Common StockMay 31, 2025 | fxempire.comScienture Holdings, Inc. Announces Leadership Transition as Suren Ajjarapu Steps Down as CEO and ChairmanMay 22, 2025 | quiverquant.comSCIENTURE Announces Executive Leadership TransitionMay 22, 2025 | globenewswire.comScienture Holdings, Inc. Announces FDA Patent Listing for Arbli™, First FDA-Approved Liquid Losartan FormulationMay 19, 2025 | quiverquant.comSCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.May 19, 2025 | globenewswire.comScienture Holdings: Q1 Earnings SnapshotMay 13, 2025 | timesunion.comScienture initiates supply chain activities by subsidiary to launch ArbliApril 24, 2025 | markets.businessinsider.comScienture Holdings, Inc. Announces Supply Chain Readiness for Launch of FDA-Approved ArbliTM Oral Suspension in July 2025April 22, 2025 | quiverquant.comSCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.April 22, 2025 | globenewswire.comScienture Holdings Divests Subsidiaries to Tollo HealthApril 11, 2025 | tipranks.comSCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment ...April 10, 2025 | seekingalpha.comScienture divests Integra Pharma Solutions, Bonum Health, Softell for $5MApril 10, 2025 | markets.businessinsider.comSCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.April 8, 2025 | globenewswire.comScienture files to sell 2.64M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comScienture CEO says focused on execution, growth, expansion for years aheadApril 4, 2025 | markets.businessinsider.comScienture Holdings, Inc. Issues Annual Letter to ShareholdersApril 3, 2025 | globenewswire.comSCNX Scienture Holdings, Inc.April 2, 2025 | seekingalpha.comScienture appoints Rath as CCO, enters agreement with SyneosMarch 26, 2025 | markets.businessinsider.comScienture Holdings, Inc. Appoints Michele Rath as Senior Vice President and Chief Commercial OfficerMarch 25, 2025 | quiverquant.comSCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales OrganizationMarch 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International Markets3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneBy Thomas Hughes | June 4, 2025View 3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneBPTS, ERNA, SCNX, and DWTX Company DescriptionsBiophytis NASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Dogwood Therapeutics NASDAQ:DWTX$4.65 -0.53 (-10.23%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.83 +0.18 (+3.87%) As of 06/13/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Eterna Therapeutics NASDAQ:ERNA$2.29 -0.08 (-3.38%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.27 -0.02 (-0.70%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Scienture NASDAQ:SCNX$1.07 -0.05 (-4.08%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.06 -0.01 (-0.98%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
